Chronic yersiniosis due to defects in the TLR 5 and NOD 2 recognition pathways

Netherlands Journal of Medicine

Volumn 68, Issue 10, 2010, Pages 310-315

  Netea, M G ^a   van der Leij, F ^a   Drenth, J P H ^a   Joosten, L A B ^a   te Morsche, R T ^a   Verweij, P ^a   de Jong, D D ^a   Kullberg, B J ^a   van der Meer, J W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Cytokine; NOD2; TLR5; Yersinia

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; FLAGELLIN; INTERLEUKIN 10; INTERLEUKIN 6; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR;

ABDOMINAL MASS; ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; GENE MUTATION; GENE SEQUENCE; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MALE; MOLECULAR RECOGNITION; NONHUMAN; YERSINIA ENTEROCOLITICA; YERSINIOSIS;

ADULT; CHRONIC DISEASE; GENOTYPE; HUMANS; MALE; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 5; YERSINIA ENTEROCOLITICA; YERSINIA INFECTIONS;

EID: 78649259613     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hoogkamp-Korstanje JA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection. 1988;16(2):81-5.
2. Naktin J, Beavis KG. Yersinia enterocolitica and Yersinia pseudotuberculosis. Clin Lab Med. 1999;19(3):523-36, vi.
3. Heesemann J, Sing A, Trulzsch K. Yersinia's stratagem: targeting innate and adaptive immune defense. Curr Opin Microbiol. 2006;9(1):55-61.
4. Cornelis GR. The Yersinia Ysc-Yop 'type III' weaponry. Nat Rev Mol Cell Biol. 2002;3(10):742-52.
5. Sing A, Rost D, Tvardovskaia N, et al. Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin-10 - mediated immunosuppression. J Exp Med. 2002;196:1017-24.
6. Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 2003;4(12):1247-53.
7. Zhang Y, Bliska JB. Role of Toll-like receptor signaling in the apoptotic response of macrophages to Yersinia infection. Infect Immun. 2003;71(3):1513-9.
8. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869-72.
9. Girardin SE, Boneca IG, Carneiro LAM, et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science. 2003;300:1584-7.
10. Bohn E, Autenrieth IB. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ cells. J Immunol. 1996;156:1458-64.
11. Bohn E, Sing A, Zumbihl R, et al. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol. 1998;160:299-307.
12. Hein J, Sing A, Di Genaro MS, Autenrieth IB. Interleukin-12 and interleukin-18 are indispensable for protective immunity against enteropathogenic Yersinia. Microb Pathog. 2001;31(4):195-9.
13. Dube PH, Handley SA, Lewis J, Miller VL. Protective role of interleukin-6 during Yersinia enterocolitica infection is mediated through the modulation of inflammatory cytokines. Infect Immun. 2004;72(6):3561-70.
14. Sing A, Reithmeier-Rost D, Granfors K, Hill J, Roggenkamp A, Heesemann J. A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence. Proc Natl Acad Sci USA. 2005;102(44):16049-54.
15. Hirschfeld M, Weis JJ, Toshchakov V, et al. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun. 2001;69:1477-82.
16. Endres S, Ghorbani R, Lonnemann G, Van der Meer JWM, Dinarello CA. Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol. 1988;49:424-38.
17. Netea MG, Kullberg BJ, de Jong D, et al. NOD2 mediates induction of the antiinflammatory signals induced by TLR2-ligands: implications for Crohn's disease. Eur J Immunol. 2004;34:2052-9.
18. Hawn TR, Verbon A, Lettinga KD, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med. 2003;198(10):1563-72.
19. Netea MG, Ferwerda G, De Jong DJ, et al. NOD2 modulates specific Toll-like receptor pathways for the induction of cytokine release. J Immunol. 2005;174:6518-23.
20. van Heel DA, Ghosh S, Hunt K, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet. 2005;365:1794-6.
21. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002;359:1661-5.
22. Brant SR, Panhuysen CI, Bailey-Wilson JE, et al. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000;119(6):1483-90.
23. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1157-63.
24. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113(9):1296-306.
25. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461-3.
26. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70.
27. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007;27(4):660-9.
28. Brubaker RR. Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun. 2003;71(7):3673-81.
29. de Kleijn EM, van Lier HJ, van der Meer JW. Fever of unknown origin (FUO). II. Diagnostic procedures in a prospective multicenter study of 167 patients. The Netherlands FUO Study Group. Medicine. (Baltimore) 1997;76(6):401-14.
30. Quintana-Murci L, Alcais A, Abel L, Casanova JL. Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol. 2007;8(11):1165-71.